文献速递眼底病与葡萄膜炎

法瑞西单抗注射后炎症与闭塞性视网膜血管炎

Inflammation and Occlusive Retinal Vasculitis Post Faricimab.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

该回顾性病例系列来自单一学术三级转诊中心(内布拉斯加大学医学中心),2023年10月至2024年8月纳入3例患者:4眼在玻璃体腔注射法瑞西单抗后发生轻度眼内炎症,其中3眼在再次注射后发生闭塞性视网膜血管炎,导致严重且不可逆的视力丧失,即使使用局部和全身类固醇治疗。结论认为,既往注射后即使发生轻度眼内炎症,再次使用同一生物制剂时也应谨慎。

要点

  • 4眼玻璃体腔注射法瑞西单抗后发生轻度眼内炎症,其中3眼再次注射后发生闭塞性视网膜血管炎。
  • 闭塞性视网膜血管炎导致严重且不可逆的视力丧失,局部和全身类固醇治疗未能逆转。
  • 1眼再次注射后未发生闭塞性视网膜血管炎,重新开始玻璃体腔注射法瑞西单抗后未再出现不良事件。

核心结论

  • 作者认为,既往注射法瑞西单抗后即使发生轻度眼内炎症,再次使用同一生物制剂时也应谨慎。
  • 作者认为,反复暴露似乎诱发了免疫记忆反应,导致闭塞性视网膜血管炎的发生。

研究设计与样本

  • 该研究为来自单一学术三级转诊中心(内布拉斯加大学医学中心)的回顾性病例系列,时间范围为2023年10月至2024年8月。
  • 研究纳入3例患者,共4眼在玻璃体腔注射法瑞西单抗后发生轻度眼内炎症,其中3眼在再次注射后发生闭塞性视网膜血管炎。
  • 2眼因新生血管性年龄相关性黄斑变性接受法瑞西单抗治疗,另2眼因糖尿病性黄斑水肿接受治疗。

主要发现

  • 4眼在法瑞西单抗注射后发生轻度眼内炎症,3眼在再次注射后发生闭塞性视网膜血管炎。
  • 闭塞性视网膜血管炎导致严重且不可逆的视力丧失,尽管使用了局部和全身类固醇治疗。
  • 1眼在再次注射后未发生闭塞性视网膜血管炎,重新开始玻璃体腔注射法瑞西单抗后未再出现不良事件。

临床怎么用

  • 作者认为,既往注射法瑞西单抗后即使发生轻度眼内炎症,再次使用同一生物制剂时也应谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials. OBJECTIVE: To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series from a single academic tertiary referral center (University of Nebraska Medical Center) from October 2023 to August 2024 included 3 patients who developed occlusive retinal vasculitis (ORV) following an initial sensitization with intravitreal faricimab. Two eyes were being treated with faricimab for nAMD, and the other 2 eyes were treated for diabetic macular edema. INTERVENTION: Patients exposed to faricimab after the prior development of mild IOI. MAIN OUTCOMES AND MEASURES: Clinical symptoms, signs, and clinical course of patients who were diagnosed with ORV following rechallenge with faricimab. RESULTS: Mild IOI developed in 4 eyes following faricimab, and ORV developed in 3 eyes with repeated challenge. This resulted in profound, irreversible vision loss, despite treatment with topical and systemic steroids. In the eye that did not develop ORV following rechallenge, there have been no repeated adverse events despite restarting intravitreal faricimab injections. CONCLUSIONS AND RELEVANCE: Given these observations with repeated challenge, caution is advisable when using the same biologic after the development of even mild IOI with prior injection. It appears an immunological memory response is elicited with these repeated exposures, resulting in the development of ORV.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bruening W, Kim S, Yeh S, et al. Inflammation and Occlusive Retinal Vasculitis Post Faricimab. JAMA Ophthalmol. 2025. PMID: 39847370. doi:10.1001/jamaophthalmol.2024.5889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。